All data are based on the daily closing price as of March 28, 2025
t
Torii Pharmaceutical
4551.TSE
31.19 USD
-0.19
-0.61%
Overview
Last close
31.19 usd
Market cap
876.68M usd
52 week high
33.14 usd
52 week low
21.80 usd
Target price
26.93 usd
Valuation
P/E
24.0543
Forward P/E
N/A
Price/Sales
2.1842
Price/Book Value
1.086
Enterprise Value
594.80M usd
EV/Revenue
1.4748
EV/EBITDA
12.4931
Key financials
Revenue TTM
392.73M usd
Gross Profit TTM
156.05M usd
EBITDA TTM
46.38M usd
Earnings per Share
1.25 usd
Dividend
N/A usd
Total assets
899.96M usd
Net debt
-18.49M usd
About
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents for renal diseases and hemodialysis, such as ENAROY tablets to treat anemia associated with CKD; Riona tablets for the treatment of hyperphosphatemia/iron deficiency anemia (IDA); and REMITCH, an oral therapeutic agent for the treatment of pruritus. The company provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; VTAMA cream, a topical treatment for atopic dermatitis and plaque psoriasis; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. It markets its products primarily through medical representatives for medical professionals. The company has a collaboration with ALK-Abelló A/S to develop and commercializes ALK's allergen immunotherapy drug targeting pollen diseases caused by grass pollen. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.